Compare QURE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QURE | COLL |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | 2015 |
| Metric | QURE | COLL |
|---|---|---|
| Price | $46.70 | $33.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $45.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 2.0M | 324.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | $13,107,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $126.12 | $8.01 |
| Revenue Next Year | $200.43 | N/A |
| P/E Ratio | ★ N/A | $83.35 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $8.73 | $29.19 |
| 52 Week High | $71.50 | $50.79 |
| Indicator | QURE | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 79.16 | 47.77 |
| Support Level | $21.63 | $31.20 |
| Resistance Level | $60.70 | $35.86 |
| Average True Range (ATR) | 2.43 | 1.32 |
| MACD | 1.72 | 0.13 |
| Stochastic Oscillator | 84.49 | 63.27 |
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.